The OJC 50: ESMO 2021 Practice Changing Early Birds 2

The Oncology Journal Club Episode 50: ESMO 2021 Early Bird Practice Changers 2

Welcome to our final ESMO 2021 Special.

As with last week’s episode, we’re focussed on early bird practice changing data.

We cover GU, Breast and GI cancers, workforce issues and much more.

So join us to digest the key ESMO updates with Eva Segelov, Craig Underhill and Hans Prenen. We hope you have a few laughs too.

We hope you enjoy listening… drop us a line on Twitter with any comments @oncologynewsaus

This Week’s Papers:

1. Fizazi, K. et al. A phase III trial with a 2×2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1.  ESMO Congress 2021, Abstract LBA5_PR. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
2. Attard, G. et al. Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. ESMO Congress 2021, Abstract LBA4_PR. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
3. Additional video resource: ESMO 2021: STAMPEDE Prostate Cancer Trial
4. Gnant, M., et al. Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. July 29, 2021. N Engl J Med 2021; 385:395-405. DOI: 10.1056/NEJMoa2104162. Access online here.
5. Del Mastro L, et al. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella. ESMO Congress 2021, Abstract 118O. Annals of Oncology (2021) 32 (suppl_5): S407-S446. 10.1016/annonc/annonc687. Access online here.
6. Alternative: Del Mastro L, et al. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Sep 15:S1470-2045(21)00352-1. doi: 10.1016/S1470-2045(21)00352-1. Epub ahead of print. PMID: 34543613. Access online here.
7. Weiss, J, et al. KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. ESMO Congress 2021, LBA6. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here. 
8. Alternative Video Resource: ESMO 2021: KRYSTAL-1 Study
9. Seligmann, J., et al. Ihibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. ESMO Congress 2021, Abstract 382O. Annals of Oncology (2021) 32 (suppl_5): S530-S582. 10.1016/annonc/annonc698. Access online here.
10. Fasching, P.A. et al. Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials. ESMO Congress 2021, Abstract 233P. Annals of Oncology (2021) 32 (suppl_5): S457-S515. 10.1016/annonc/annonc689. Access online here.
11. Rugo, H. et al. KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. ESMO Congress 2021, Abstract LBA16. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
12. Additional video resource: ESMO 2021: The KEYNOTE-355 study

This Week’s Quick Bites:

1. Agarwal, N. et al. Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study. ESMO Congress 2021, Abstract LBA24. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
2. Ludford, K. et al. Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency. ESMO Congress 2021, Abstract 1758O. Annals of Oncology (2021) 32 (suppl_5): S1211-S1226. 10.1016/annonc/annonc716. Access online here.
3. Pfister, C. et al. Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial. ESMO Congress 2021, Abstract 652O. Annals of Oncology (2021) 32 (suppl_5): S678-S724. 10.1016/annonc/annonc675. Access online here.
4. Conroy, T. et al. Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC). ESMO Congress 2021, Abstract LBA57. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
5. Additional Video Resource: ESMO 2021: PRODIGE 24 Trial
6. Lim, KHJ, et al. The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series. ESMO 2021 Congress, Abstract 1561O. Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713. Access online here.
7. Qi, C, et al. 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system. ESMO Congress 2021, Abstract 1372O. Annals of Oncology (2021) 32 (suppl_5): S1040-S1075. 10.1016/annonc/annonc708. Access online here.
8. Walter, T et al. Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC). ESMO Congress 2021, Abstract LBA41. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.

Other Episodes Mentioned:

The OJC Episode 45: Challenges of Cancer Care for the LGBTQ+ Community – includes discussion of St. Gallen International Consensus Guidelines for treatment of early breast cancer

The OJC 49: ESMO Practice Changing Early Birds

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

You can find Eva on Twitter here: @profevasegelov

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

You can find Hans on Twitter here: @HPrenen

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on Twitter here: @CraigUnderhill 

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen and Graham Knowles.

Connect with us on Twitter @OncologyNewsAus